Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
Shares continue trading on Nasdaq during the cure period, but failure to regain compliance would trigger a delisting notification.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene (EVGN) received an additional 180-day period from Nasdaq to regain compliance with its minimum bid price requirement by March 29, 2027. The initial deadline was September 28, 2026, following a March 30 notice that its closing bid price had been below $1.00 for 30 consecutive business days.
Compliance requires a closing bid price of at least $1.00 for at least ten consecutive business days. Failure to meet listing requirements by the extended deadline would trigger a delisting notification. Evogene intends to consider alternatives, potentially including a reverse share split, if the deficiency persists. The letter has no immediate effect on Nasdaq trading and no bearing on its Tel Aviv Stock Exchange listing.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNasdaq granted 180 additional calendar days, until March 29, 2027, to regain bid price compliance.
- Minor pointNasdaq trading continues during the cure period; the letter has no immediate listing effect.
Negative
- Moderate pointMinimum bid price deficiency followed 30 consecutive business days with closing bids below $1.00.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Delisting notification would follow failure to meet bid price or other listing requirements by March 29, 2027.
Details
Market Reaction – EVGN
On Sep 30, the day this news came out, the latest delayed price for EVGN is 2.44% above the previous close. Argus tracked a peak move of +2.4% during the session. Our momentum scanner has recorded 20 alerts for this stock so far that day. The latest delayed price is $0.42. Relative volume is exceptionally heavy at 6486.2x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Minimum bid price
- Below $1.00 per share
- The reported Nasdaq listing deficiency
- Additional compliance period
- 180 calendar days, until March 29, 2027
- Additional time granted to regain minimum bid price compliance
- Compliance price condition
- At least $1.00 for 10 consecutive business days
- Condition to regain compliance during the additional period
- Potential delisting notification
- If compliance is not demonstrated by March 29, 2027
- Nasdaq staff would provide written notification that the securities will be delisted
Key Terms
AI-generated analysis. How Rhea-AI works. Not financial advice.
REHOVOT,
According to the Letter, the Nasdaq staff determined that the Company is eligible for an additional 180 calendar day period, until March 29, 2027, to regain compliance with the minimum bid price requirement. The Company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least
If the Company does not demonstrate compliance (with the bid price requirement or with any other listing requirements) prior to the end of the 180-day period ending March 29, 2027, Nasdaq's staff will provide written notification that the Company's securities will be delisted.
It is noted that Evogene's continued listing on Nasdaq remains a key priority for the Company. Should the situation not resolve itself over the above-mentioned timeframe, the Company intends to consider other available options to cure the deficiency and regain compliance with the minimum bid requirement within the compliance period, including potentially affecting a reverse share split among other alternatives.
The Letter from Nasdaq has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares on Nasdaq, and during the aforementioned cure period, the Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "EVGN". It is further noted that the Letter from Nasdaq has no bearing on Evogene's listing on the Tel Aviv Stock Exchange, where its ordinary shares are traded under the ticker symbol "EVGN".
About Evogene Ltd.:
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag-chemical products. At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates," "designed to," "intended to," "with the goal of," or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses its ability to regain compliance under Nasdaq's Listing Qualification requirements including by potentially affecting a reverse share split to regain the
Investor Relations Contact:
ir@evogene.com
Tel: +972-8-9311901
View original content to download multimedia:https://www.prnewswire.com/news-releases/evogene-reports-nasdaq-grants-additional-180-day-period-to-regain-minimum-bid-price-compliance-302894297.html
SOURCE Evogene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Evogene's new Nasdaq compliance deadline?
Evogene has until March 29, 2027 to regain minimum bid price compliance. Nasdaq granted an additional 180 calendar days after the initial compliance period ended September 28, 2026.
How can Evogene regain Nasdaq minimum bid price compliance?
Evogene must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during the extended compliance period. Nasdaq would then provide written confirmation of compliance and close the matter.